Skip links

Leadership

Our global expertise is your asset.
We rethink innovation.

By coupling our unmatched experience in transformative technologies such as Artificial Intelligence and Blockchain with vast competencies in healthcare, Life Sciences, Biotech, and Pharma, we rethink innovation. Alongside unparalleled Private Equity, Policy, and Regulation expertise.

As international renowned experts we serve C-Suites, leading multinationals to start-ups, governments, investors, academia, and non-profit organizations worldwide. By guiding our clients in their digital transformation and innovation strategies with pragmatic and actionable solutions.

Nicole Formica-Schiller

CEO & Founder
formicaschiller.com
More about Nicole

Mel Formica

Member of the Board
More about Mel

Nicole Formica-Schiller

CEO & Founder
formicaschiller.com

Nicole Formica-Schiller stands for the new digital generation driving Artificial Intelligence (AI), Blockchain, Disruptive Technologies and for a sustainable digital future. Her trademark: interdisciplinary, dynamic, pragmatic!

She is considered an international expert, featured in E-Health-Com, Frankfurter Allgemeine Zeitung (FAZ), Tagesspiegel “Background Digitalisation & AI”, Doctors І today, Handelsblatt etc.

Known for her ability to translate complex digital trends of tomorrow into use cases of today. Including socio- and geopolitical, ethical and economic impacts on institutions, societies, and markets. As well as the role of Big Tech.

Her “top pre-order” listed book “Artificial Intelligence and Blockchain in Healthcare: How COVID-19 and future-oriented technologies are revolutionizing the status quo”, published in 2021, is considered a digital wake-up call!

As CEO & Founder of Pamanicor Health, Nicole Formica-Schiller drives digital transformation.

She is an impulse generator directly exchanging with politics, industry, academics, and commissions (Data Ethics Commission German Federal Government, Swiss Crypto Valley Blockchain Association etc.). At Germany’s largest industry association for Artificial Intelligence, KI-Bundesverband, she is Head of the Steering Committee Federal Task Force “EU AI-Regulation”, co-author “EU Regulation of Artificial Intelligence”, advisor to the Task Force “AI & Health” as well as Board member and Spokesperson for the state of Bavaria.

Selected by Forbes for “most innovative ideas” in AI and Blockchain. Described in the media as “Digital Disruptor“.

As a digital thought leader, Nicole Formica-Schiller is a sought-after speaker at national and international levels. As a mentor for startups, diversity & inclusion, she inspires not only a new generation of founders. But all those who want to use digital progress in the best interest of society and the economic benefit of a country.

Before founding Pamanicor Health, Nicole Formica-Schiller worked in London, Kuala Lumpur, Germany, Hong Kong, Moscow, Switzerland, e.g. as Liaison Officer for the CEO of Nord Stream,  involved in one of Europe’s largest stakeholder consultations paving the way for European governmental approvals across different jurisdictions, at Freshfields Bruckhaus Deringer’s IT/IP, Allianz, Shearman Sterling, Munich Re. She graduated as an Attorney-at-law from Ludwig-Maximilians-University Munich, Germany, with an additional economics and business degree focused on finance and marketing.

Recent articles

„We help our customers implement disruptive technologies and shape the future“

Mel Formica, PhD, MBA

Member of the Board

Regarded as one of the leading transformation leaders in Life Sciences, Biopharmaceuticals and Digital Healthcare, Mel Formica is globally recognized as an innovative and sought-after healthcare executive. He is a highly respected international expert with proven P&L and operational leadership experience as well as M&A advisory expertise. An innovator in developing distinctive market entry and commercial strategies for early-stage businesses, combining customer insight, vision, and creativity. Focused at the forefront of transformations in Disruptive Technologies, patient level data and improved quality of care.

With over 20+ years of industry experience in leadership roles at world leading companies such as at Evidera / PPD, Takeda Pharmaceuticals, Amgen Inc., IMS Health and Abbot Laboratories across Australia, US, China, Japan, Switzerland and Europe. His extensive experience spans clinical research, marketing, strategic consulting, value & access, and evidence generation which makes him a sought-after leader for C-Suites and innovative companies worldwide. As an operating advisor to private equity firms focused on healthcare, he challenges portfolio companies to think about long-term changes and strategically position new opportunities in the market.

Mel Formica is well known in the industry as a pioneer of breakthrough concepts, global biopharmaceutical product launches and new organizational models leading to improved operating efficiency and driving business growth. With international experience to successfully drive top and bottom-line growth through building and leading complex organizations, strategic transformations, turnarounds as well as leading cross-functional teams spanning multiple geographies and complex matrix organizations.

With a vision to change the way the industry thinks, acts, and operates, Mel Formica is the co-founder of the BCG Market Access Roundtable and the London School of Economics and Political Science (LSE) Market Access Academy. He has also been featured in numerous industry and scientific publications and received various awards.

His academic and research appointments included Assistant Professor at the College of Physicians and Surgeons of Columbia University, New York, St. Luke’s-Roosevelt Hospital Center, New York and Helen Hayes Hospital, New York, US.

Mel Formica earned his PhD (Medicine) at the University of Melbourne, Australia. He completed his post-doctoral training in the Department of Medicine at Columbia University, New York, US. In addition, he holds an Executive MBA from the Lubin School of Business, Pace University, New York, US.

Recent articles

The expanding role of real-world evidence in the regulatory environment